黑色素瘤分化轨迹决定对预存CD8+肿瘤浸润淋巴细胞的敏感性
该研究以MAPK抑制剂处理的BRAFV600突变黑色素瘤为模型,将人类黑色素瘤状态转变与CD8+ T细胞反应相关联。研究发现同基因黑色素瘤细胞在单用BRAF抑制剂或BRAFi/MEKi联合治疗下可沿不同分化轨迹演化,产生BRAFi诱导的高分化耐药亚型和BRAFi/MEKi诱导的去分化耐药亚型。利用患者来源的自体CD8+肿瘤浸润淋巴细胞(TILs),研究证明高分化轨迹的肿瘤细胞持续获得对肿瘤反应性CD8+ TILs的敏感性,而去分化轨迹的肿瘤细胞则获得T细胞抵抗,部分由于分化抗原丢失。
要点
- 黑色素瘤细胞在MAPK抑制剂治疗下沿不同分化轨迹演化。
- 高分化轨迹肿瘤细胞对CD8+ TILs敏感性持续增加。
- 去分化轨迹肿瘤细胞因分化抗原丢失而获得T细胞抵抗。
核心结论
- MAPKi诱导的临时性和稳定性表型改变与T细胞功能紧密相关,影响靶向治疗与免疫治疗的最佳联合策略。
研究设计与样本
- 以MAPK抑制剂处理的BRAFV600突变黑色素瘤为模型,连接人类黑色素瘤状态转变与CD8+ T细胞反应。
主要发现
- 同基因黑色素瘤细胞在单用BRAFi或BRAFi/MEKi治疗下可沿不同分化轨迹演化,产生BRAFi诱导的高分化耐药亚型和BRAFi/MEKi诱导的去分化耐药亚型。
- 高分化轨迹的肿瘤细胞持续获得对肿瘤反应性CD8+ TILs的敏感性。
- 去分化轨迹的肿瘤细胞获得T细胞抵抗,部分由于分化抗原丢失。
临床怎么用
- 提示靶向治疗与免疫治疗联合时需考虑黑色素瘤分化状态对T细胞敏感性的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The highly plastic nature of melanoma enables its transition among diverse cell states to survive hostile conditions. However, the interplay between specific tumor cell states and intratumoral T cells remains poorly defined. With MAPK inhibitor‒treated BRAFV600-mutant tumors as models, we linked human melanoma state transition to CD8+ T cell responses. Repeatedly, we observed that isogenic melanoma cells could evolve along distinct differentiation trajectories on single BRAF inhibitor (BRAFi) treatment or dual BRAFi/MEKi treatment, resulting in BRAFi‒induced hyperdifferentiated and BRAFi/MEKi‒induced dedifferentiated resistant subtypes. Taking advantage of patient-derived autologous CD8+ tumor-infiltrating lymphocytes (TILs), we demonstrate that progressive melanoma cell state transition profoundly affects TIL function. Tumor cells along the hyperdifferentiation trajectory continuously gained sensitivity toward tumor-reactive CD8+ TILs, whereas those in the dedifferentiation trajectory acquired T cell resistance in part owing to the loss of differentiation antigens. Overall, our data reveal the tight connection of MAPKi‒induced temporary (drug-tolerant transition state) and stable (resistant state) phenotype alterations with T cell function and further broaden the current knowledge on melanoma plasticity in terms of sculpting local antitumor immune responses, with implications for guiding the optimal combination of targeted therapy and immunotherapy.
引用
- Harbers FN, Thier B, Stupia S, et al. Melanoma Differentiation Trajectories Determine Sensitivity toward Pre-Existing CD8+ Tumor-Infiltrating Lymphocytes. J Invest Dermatol. 2021. PMID: 33798535. doi:10.1016/j.jid.2021.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。